CA3187578A1 - Methode de traitement de sous-types de lma a l'aide d'agents de depletion de l'arginine - Google Patents

Methode de traitement de sous-types de lma a l'aide d'agents de depletion de l'arginine

Info

Publication number
CA3187578A1
CA3187578A1 CA3187578A CA3187578A CA3187578A1 CA 3187578 A1 CA3187578 A1 CA 3187578A1 CA 3187578 A CA3187578 A CA 3187578A CA 3187578 A CA3187578 A CA 3187578A CA 3187578 A1 CA3187578 A1 CA 3187578A1
Authority
CA
Canada
Prior art keywords
arginine
depleting agent
leukemia
acute
aml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3187578A
Other languages
English (en)
Inventor
Sui Yi Kwok
Norman Fung Man Wai
Terence Shau Yin WAI
Yun Chung Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vision Global Holdings Ltd
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of CA3187578A1 publication Critical patent/CA3187578A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon l'invention, une méthode de traitement de la leucémie myéloïde aiguë (LMA) chez un sujet qui en a besoin comprend l'administration d'une quantité thérapeutiquement efficace d'un agent de déplétion de l'arginine au sujet, la LMA étant du sous-type M0 (leucémie myéloblastique aigüe sans différenciation), M2 (leucémie myéloblastique aigüe avec maturation), M4 (leucémie myéloblastique aigüe avec maturation), M4 eos (leucémie myélomonocytique aigüe avec éosinophilie), M5 (leucémie monocytique aigüe), M6 (leucémie érythroïde aigüe) ou M7 (leucémie mégakaryoblastique aigüe) du système franco-américano-britannique (FAB). L'invention concerne également un médicament comportant un agent de déplétion de l'arginine pour traiter la LMA chez un sujet qui en a besoin, la LMA étant du sous-type M0 (leucémie myéloblastique aigüe sans différenciation), M2 (leucémie myéloblastique aigüe avec maturation), M4 (leucémie myéloblastique aigüe avec maturation), M4 eos (leucémie myélomonocytique aigüe avec éosinophilie), M5 (leucémie monocytique aigüe), M6 (leucémie érythroïde aigüe) ou M7 (leucémie mégakaryoblastique aigüe) du système franco-américano-britannique (FAB).
CA3187578A 2020-06-29 2020-06-29 Methode de traitement de sous-types de lma a l'aide d'agents de depletion de l'arginine Pending CA3187578A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/098681 WO2022000151A1 (fr) 2020-06-29 2020-06-29 Méthode de traitement de sous-types de lma à l'aide d'agents de déplétion de l'arginine

Publications (1)

Publication Number Publication Date
CA3187578A1 true CA3187578A1 (fr) 2022-01-06

Family

ID=79317763

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3187578A Pending CA3187578A1 (fr) 2020-06-29 2020-06-29 Methode de traitement de sous-types de lma a l'aide d'agents de depletion de l'arginine

Country Status (6)

Country Link
EP (1) EP4153167A4 (fr)
KR (1) KR20230104110A (fr)
CN (1) CN115697320A (fr)
CA (1) CA3187578A1 (fr)
TW (1) TW202206095A (fr)
WO (1) WO2022000151A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210162028A1 (en) * 2019-12-02 2021-06-03 The Hong Kong Polytechnic University Methods for Inducing Intermittent Fasting and Modulating Autophagy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015512A1 (fr) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Arginine déiminase modifiée
AU2012330497B2 (en) * 2012-04-04 2016-08-04 Polaris Group Methods of treating with arginine deiminase
WO2018009528A1 (fr) * 2016-07-05 2018-01-11 Tdw Group Immunothérapies anticancéreuses combinées comprenant des agents d'appauvrissement en arginine
EP3515495A4 (fr) * 2016-09-26 2020-08-26 Ensemble Group Holdings Procédés d'évaluation et de traitement du cancer chez des sujets ayant des systèmes lymphatiques dysrégulés

Also Published As

Publication number Publication date
WO2022000151A1 (fr) 2022-01-06
TW202206095A (zh) 2022-02-16
EP4153167A1 (fr) 2023-03-29
KR20230104110A (ko) 2023-07-07
EP4153167A4 (fr) 2024-02-28
CN115697320A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
Patel et al. Current advances in the treatment of BRAF-mutant melanoma
Guo et al. Thrombin-responsive, brain-targeting nanoparticles for improved stroke therapy
JP2011526626A5 (fr)
JP7373998B2 (ja) 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
JP2009543868A (ja) 癌治療に関する方法および組成物
WO2020181235A1 (fr) Molécules variantes d'il-10 et méthodes de traitement d'une maladie inflammatoire et oncologie
EP3448363B1 (fr) Nouvelle composition pharmaceutique comprenant des particules comprenant un complexe d'un polyribonucléotide double brin et une polyalkylèneimine
JP2012504423A (ja) 治療用リボヌクレアーゼ
US20240076337A1 (en) Dual cytokine fusion proteins comprising il-10
KR20140009262A (ko) 항염증 조성물
CN109963597B (zh) 聚乙二醇化血管内皮抑制素类似物及其应用
Ward et al. Clinical experience of cancer immunotherapy integrated with oleic acid complexed with de-glycosylated vitamin D binding protein
US20210401952A1 (en) Method of treating AML subtypes using arginine-depleting agents
WO2022000151A1 (fr) Méthode de traitement de sous-types de lma à l'aide d'agents de déplétion de l'arginine
WO2019213686A1 (fr) Compositions thérapeutiques et leurs utilisations
US20230287075A1 (en) Dual cytokine fusion proteins comprising multi-subunit cytokines
EP4151198A1 (fr) Médicament contenant des nanoparticules d'or
EP3142692B1 (fr) Compositions contenant l'il-31 et leurs utilisations
JP2022104920A (ja) 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
TWI359030B (en) Treatment of cellular proliferative disorders
KR20180129585A (ko) Mage-1에 특이적으로 결합하는 압타머 및 이의 용도
US10874711B2 (en) Use of annexin V to reduce the spread of intracellular pathogens
TWI676683B (zh) 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶
WO2018088933A1 (fr) Effets anti-tumoraux d'un vecteur viral codant pour un récepteur de type toll et un agoniste de récepteur de type toll
Nusbaum Potential use of IgA protease therapy in IgA myeloma patients